Clinical and Translational Radiation Oncology最新文献

{"title":"Preoperative radiosurgery for brain metastases (PREOP-1): A feasibility trial","authors":"S Rogers ,&nbsp;L Schwyzer ,&nbsp;N Lomax ,&nbsp;S Alonso ,&nbsp;T Lazeroms ,&nbsp;S Gomez ,&nbsp;K Diahovets ,&nbsp;I Fischer ,&nbsp;S Schwenne ,&nbsp;A Ademaj ,&nbsp;S Berkmann ,&nbsp;A Tortora ,&nbsp;S Marbacher ,&nbsp;L Remonda ,&nbsp;G.A. Schubert ,&nbsp;O Riesterer","doi":"10.1016/j.ctro.2024.100798","DOIUrl":"10.1016/j.ctro.2024.100798","url":null,"abstract":"<div><h3>Purpose</h3><p>Preoperative radiosurgery (SRS) of brain metastases (BM) aims to achieve cavity local control with a reduction in leptomeningeal relapse (LMD) and without additional radionecrosis compared to postoperative SRS. We present the final results of a prospective feasibility trial of linac-based stereotactic radiosurgery (SRS) prior to neurosurgical resection of a brain metastasis (PREOP-1).</p></div><div><h3>Methods</h3><p>Eligibility criteria included a BM up to 4 cm in diameter for elective resection. The primary endpoint was the feasibility of delivering linac-based preoperative SRS in all patients prior to anticipated gross tumour resection. Secondary endpoints included rates of LMD, local control and overall survival. Exploratory endpoints were the level of expression of immunological and proliferative markers.</p></div><div><h3>Results</h3><p>Thirteen patients of median age 65 years (range 41–77) were recruited. Twelve patients (92 %) received preoperative radiosurgery and metastasectomy and one patient went directly to surgery and received postoperative SRS, thus the primary endpoint was not met. The median time between referral and preoperative SRS was 6.5 working days (1–10) and from SRS to neurosurgery was 1 day (0–5). The median prescribed dose was 16 Gy (14–19) to a median planning target volume of 12.7 cm³ (5.9–26.1). Five patients completed 12-month follow-up after preoperative SRS without local recurrence or leptomeningeal disease. The patient who received postoperative FSRT developed LMD after six months. There was one transient toxicity (grade 2 alopecia) and nine patients have died from extracranial causes. Patients reported significant improvement in motor weakness at 6 months (P = 0.04). No pattern in changes of marker expression was observed.</p></div><div><h3>Conclusion</h3><p>In patients with large brain metastasis without raised intracranial pressure, linac-based preoperative SRS was feasible in 12/13 patients and safe in 12/12 patients without any surgical delay or intracranial complications.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100798"},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000752/pdfft?md5=8bedf1e1be19cda7cd5a49183fcfda91&pid=1-s2.0-S2405630824000752-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141279056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis of randomised controlled trials","authors":"Marcin Miszczyk ,&nbsp;Tao Wu ,&nbsp;Kasper Kuna ,&nbsp;Magdalena Stankiewicz ,&nbsp;Emilia Staniewska ,&nbsp;Zuzanna Nowicka ,&nbsp;Ziqin Chen ,&nbsp;Loren K. Mell ,&nbsp;Joachim Widder ,&nbsp;Maximilian Schmidt ,&nbsp;Rafał Tarnawski ,&nbsp;Paweł Rajwa ,&nbsp;Shahrokh F. Shariat ,&nbsp;Pixiao Zhou","doi":"10.1016/j.ctro.2024.100801","DOIUrl":"https://doi.org/10.1016/j.ctro.2024.100801","url":null,"abstract":"<div><h3>Background</h3><p>Concurrent chemoradiotherapy (CRT) is the standard treatment for locally advanced cervical cancer. We investigated how additional bone marrow sparing (BMS) affects the clinical outcomes.</p></div><div><h3>Methods</h3><p>We queried MEDLINE, Embase, Web of Science Core Collection, Google Scholar, Sinomed, CNKI, and Wanfang databases for articles published in English or Chinese between 2010/01/01 and 2023/10/31. Full-text manuscripts of prospective, randomised trials on BMS in cervical cancer patients treated with definitive or postoperative CRT were included. Risk of bias (RoB) was assessed using Cochrane Collaboration’s RoB tool. Random-effects models were used for the <em>meta</em>-analysis.</p></div><div><h3>Results</h3><p>A total of 17 trials encompassing 1297 patients were included. The majority were single-centre trials (n = 1268) performed in China (n = 1128). Most trials used CT-based anatomical BMS (n = 1076). There was a comparable representation of trials in the definitive (n = 655) and postoperative (n = 582) settings, and the remaining trials included both.</p><p>Twelve studies reported data on G ≥ 3 (n = 782) and G ≥ 2 (n = 754) haematologic adverse events. Both G ≥ 3 (OR 0.39; 95 % CI 0.28–0.55; p &lt; 0.001) and G ≥ 2 (OR 0.29; 95 % CI 0.18–0.46; p &lt; 0.001) toxicity were significantly lowered, favouring BMS. Seven studies (n = 635) reported data on chemotherapy interruptions, defined as receiving less than five cycles of cisplatin, which were significantly less frequent in patients treated with BMS (OR 0.44; 95 % CI 0.24–0.81; p = 0.016). There was no evidence of increased gastrointestinal or genitourinary toxicity.</p><p>There were no signs of significant heterogeneity. Four studies were assessed as high RoB; sensitivity analyses excluding these provided comparable results for main outcomes. The main limitations include heterogeneity in BMS methodology between studies, low representation of populations most affected by cervical cancer, and insufficient data to assess survival outcomes.</p></div><div><h3>Conclusions</h3><p>The addition of BMS to definitive CRT in cervical cancer patients decreases hematologic toxicity and the frequency of interruptions in concurrent chemotherapy. However, data are insufficient to verify the impact on survival and disease control.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100801"},"PeriodicalIF":3.1,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000788/pdfft?md5=1bcd6059d7fbc80640346c4814303c26&pid=1-s2.0-S2405630824000788-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141289456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weekly ultra-hypofractionated radiotherapy in localised prostate cancer","authors":"Nora Sundahl ,&nbsp;Douglas Brand ,&nbsp;Chris Parker ,&nbsp;David Dearnaley ,&nbsp;Alison Tree ,&nbsp;Angela Pathmanathan ,&nbsp;Yae-eun Suh ,&nbsp;Nicholas Van As ,&nbsp;Rosalind Eeles ,&nbsp;Vincent Khoo ,&nbsp;Robert Huddart ,&nbsp;Julia Murray","doi":"10.1016/j.ctro.2024.100800","DOIUrl":"https://doi.org/10.1016/j.ctro.2024.100800","url":null,"abstract":"<div><h3>Background</h3><p>Moderately hypofractionated radiotherapy regimens or stereotactic body radiotherapy (SBRT) are standard of care for localised prostate cancer. However, some patients are unable or unwilling to travel daily to the radiotherapy department and do not have access to, or are not candidates for, SBRT. For many years, The Royal Marsden Hospital NHS Foundation Trust has offered a weekly ultra-hypofractionated radiotherapy regimen to the prostate (36 Gy in 6 weekly fractions) to patients unable/unwilling to travel daily.</p></div><div><h3>Methods</h3><p>The current study is a retrospective analysis of all patients with non-metastatic localised prostate cancer receiving this treatment schedule from 2010 to 2015.</p></div><div><h3>Results</h3><p>A total of 140 patients were included in the analysis, of whom 86 % presented with high risk disease, with 31 % having Gleason Grade Group 4 or 5 disease and 48 % T3 disease or higher. All patients received hormone treatment, and there was often a long interval between start of hormone treatment and start of radiotherapy (median of 11 months), with 34 % of all patients having progressed to non-metastatic castrate-resistant disease prior to start of radiotherapy. Median follow-up was 52 months. Median progression-free survival (PFS) and overall survival (OS) for the whole group was 70 months and 72 months, respectively. PFS and OS in patients with hormone-sensitive disease at time of radiotherapy was not reached and 75 months, respectively; and in patients with castrate-resistant disease at time of radiotherapy it was 20 months and 61 months, respectively.</p></div><div><h3>Conclusion</h3><p>Our data shows that a weekly ultra-hypofractionated radiotherapy regimen for prostate cancer could be an option in those patients for whom daily treatment or SBRT is not an option.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100800"},"PeriodicalIF":3.1,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000776/pdfft?md5=d9139e1348594c915c15b356204494d3&pid=1-s2.0-S2405630824000776-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141240820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram for radiation-induced lymphopenia in patients receiving intensity-modulated radiotherapy based-chemoradiation therapy for newly diagnosed glioblastoma: A multi-institutional study","authors":"Nalee Kim ,&nbsp;Joongyo Lee ,&nbsp;Hyunju Shin ,&nbsp;Jungwook Shin ,&nbsp;Do-Hyun Nam ,&nbsp;Jung-Il Lee ,&nbsp;Ho Jun Seol ,&nbsp;Doo-Sik Kong ,&nbsp;Jung Won Choi ,&nbsp;Kyuha Chong ,&nbsp;Won Jae Lee ,&nbsp;Jong Hee Chang ,&nbsp;Seok-Gu Kang ,&nbsp;Ju Hyung Moon ,&nbsp;Jaeho Cho ,&nbsp;Do Hoon Lim ,&nbsp;Hong In Yoon","doi":"10.1016/j.ctro.2024.100799","DOIUrl":"10.1016/j.ctro.2024.100799","url":null,"abstract":"<div><h3>Purpose</h3><p>Severe lymphopenia (SLP) has emerged as a significant prognostic factor in glioblastoma. Intensity-modulated radiation therapy (IMRT)-based radiation therapy (RT) is suggested to minimize the risk of SLP. This study aimed to evaluate SLP incidence based on multi-institutional database in patients with GBM treated with IMRT and develop a predictive nomogram.</p></div><div><h3>Patients and methods</h3><p>This retrospective study reviewed data from 348 patients treated with IMRT-based concurrent chemoradiation therapy (CCRT) at two major hospitals from 2016 to 2021. After multivariate regression analysis, a nomogram was developed and internally validated to predict SLP risk.</p></div><div><h3>Results</h3><p>During treatment course, 21.0% of patients developed SLP and SLP was associated with poor overall survival outcomes in patients with GBM. A newly developed nomogram, incorporating gender, pre-CCRT absolute lymphocyte count, and brain mean dose, demonstrated fair predictive accuracy (AUC 0.723).</p></div><div><h3>Conclusions</h3><p>This study provides the first nomogram for predicting SLP in patients with GBM treated with IMRT-based CCRT, with acceptable predictive accuracy. The findings underscore the need for dose optimization and radiation planning to minimize SLP risk. Further external validation is crucial for adopting this nomogram in clinical practice.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100799"},"PeriodicalIF":3.1,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000764/pdfft?md5=df13a263510dabb65f14143dcf4346fe&pid=1-s2.0-S2405630824000764-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141143586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of a deep learning CBCT auto-segmentation software for prostate adaptive radiation therapy","authors":"Lorenzo Radici ,&nbsp;Cristina Piva ,&nbsp;Valeria Casanova Borca ,&nbsp;Domenico Cante ,&nbsp;Silvia Ferrario ,&nbsp;Marina Paolini ,&nbsp;Laura Cabras ,&nbsp;Edoardo Petrucci ,&nbsp;Pierfrancesco Franco ,&nbsp;Maria Rosa La Porta ,&nbsp;Massimo Pasquino","doi":"10.1016/j.ctro.2024.100796","DOIUrl":"10.1016/j.ctro.2024.100796","url":null,"abstract":"<div><h3>Purpose</h3><p>Aim of the present study is to characterize a deep learning-based auto-segmentation software (DL) for prostate cone beam computed tomography (CBCT) images and to evaluate its applicability in clinical adaptive radiation therapy routine.</p></div><div><h3>Materials and methods</h3><p>Ten patients, who received exclusive radiation therapy with definitive intent on the prostate gland and seminal vesicles, were selected. Femoral heads, bladder, rectum, prostate, and seminal vesicles were retrospectively contoured by four different expert radiation oncologists on patients CBCT, acquired during treatment. Consensus contours (CC) were generated starting from these data and compared with those created by DL with different algorithms, trained on CBCT (DL-CBCT) or computed tomography (DL-CT). Dice similarity coefficient (DSC), centre of mass (COM) shift and volume relative variation (VRV) were chosen as comparison metrics. Since no tolerance limit can be defined, results were also compared with the inter-operator variability (IOV), using the same metrics.</p></div><div><h3>Results</h3><p>The best agreement between DL and CC was observed for femoral heads (DSC of 0.96 for both DL-CBCT and DL-CT). Performance worsened for low-contrast soft tissue organs: the worst results were found for seminal vesicles (DSC of 0.70 and 0.59 for DL-CBCT and DL-CT, respectively). The analysis shows that it is appropriate to use algorithms trained on the specific imaging modality. Furthermore, the statistical analysis showed that, for almost all considered structures, there is no significant difference between DL-CBCT and human operator in terms of IOV.</p></div><div><h3>Conclusions</h3><p>The accuracy of DL-CBCT is in accordance with CC; its use in clinical practice is justified by the comparison with the inter-operator variability.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100796"},"PeriodicalIF":3.1,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000739/pdfft?md5=d28358333a8c4013e5b7e2d99d412a66&pid=1-s2.0-S2405630824000739-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol","authors":"Guus Grimbergen ,&nbsp;Hidde Eijkelenkamp ,&nbsp;Louk M.W. Snoeren ,&nbsp;Rana Bahij ,&nbsp;Uffe Bernchou ,&nbsp;Erik van der Bijl ,&nbsp;Hanne D. Heerkens ,&nbsp;Shawn Binda ,&nbsp;Sylvia S.W. Ng ,&nbsp;Christelle Bouchart ,&nbsp;Zelda Paquier ,&nbsp;Kerryn Brown ,&nbsp;Richard Khor ,&nbsp;Robert Chuter ,&nbsp;Linnéa Freear ,&nbsp;Alex Dunlop ,&nbsp;Robert Adam Mitchell ,&nbsp;Beth A. Erickson ,&nbsp;William A. Hall ,&nbsp;Paola Godoy Scripes ,&nbsp;Gert J. Meijer","doi":"10.1016/j.ctro.2024.100797","DOIUrl":"https://doi.org/10.1016/j.ctro.2024.100797","url":null,"abstract":"<div><h3>Background and purpose</h3><p>Treatment planning for MR-guided stereotactic body radiotherapy (SBRT) for pancreatic tumors can be challenging, leading to a wide variation of protocols and practices. This study aimed to harmonize treatment planning by developing a consensus planning protocol for MR-guided pancreas SBRT on a 1.5 T MR-Linac.</p></div><div><h3>Materials and methods</h3><p>A consortium was founded of thirteen centers that treat pancreatic tumors on a 1.5 T MR-Linac. A phased planning exercise was conducted in which centers iteratively created treatment plans for two cases of pancreatic cancer. Each phase was followed by a meeting where the instructions for the next phase were determined. After three phases, a consensus protocol was reached.</p></div><div><h3>Results</h3><p>In the benchmarking phase (phase I), substantial variation between the SBRT protocols became apparent (for example, the gross tumor volume (GTV) <em>D</em>_99% ranged between 36.8 – 53.7 Gy for case 1, 22.6 – 35.5 Gy for case 2). The next phase involved planning according to the same basic dosimetric objectives, constraints, and planning margins (phase II), which led to a large degree of harmonization (GTV <em>D</em>_99% range: 47.9–53.6 Gy for case 1, 33.9–36.6 Gy for case 2). In phase III, the final consensus protocol was formulated in a treatment planning system template and again used for treatment planning. This not only resulted in further dosimetric harmonization (GTV <em>D</em>_99% range: 48.2–50.9 Gy for case 1, 33.5–36.0 Gy for case 2) but also in less variation of estimated treatment delivery times.</p></div><div><h3>Conclusion</h3><p>A global consensus protocol has been developed for treatment planning for MR-guided pancreatic SBRT on a 1.5 T MR-Linac. Aside from harmonizing the large variation in the current clinical practice, this protocol can provide a starting point for centers that are planning to treat pancreatic tumors on MR-Linac systems.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100797"},"PeriodicalIF":3.1,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000740/pdfft?md5=7e850715a1df6ebd0578f0d466ad8199&pid=1-s2.0-S2405630824000740-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between tumor cell in air space and treatment outcomes in early-stage lung cancer treated with stereotactic body radiation therapy","authors":"Kenji Makita ,&nbsp;Yasushi Hamamoto ,&nbsp;Hiromitsu Kanzaki ,&nbsp;Kei Nagasaki ,&nbsp;Hirokazu Matsuki ,&nbsp;Koji Inoue ,&nbsp;Toshiyuki Kozuki","doi":"10.1016/j.ctro.2024.100795","DOIUrl":"10.1016/j.ctro.2024.100795","url":null,"abstract":"<div><h3>Background and purpose</h3><p>Spread-through air space (STAS) is an unfavorable factor in patients with lung cancer treated with surgery. However, the relationship between the treatment outcomes of stereotactic body radiation therapy (SBRT) for lung cancer and STAS has not been adequately investigated. This study aimed to evaluate the impact of tumor cells in the air space (TCIAS), which show a STAS burden, on treatment outcomes in patients with early-stage lung cancer treated with SBRT.</p></div><div><h3>Materials and methods</h3><p>Data of patients who underwent SBRT for early-stage lung cancer treated with SBRT were retrospectively reviewed. The influence of the TCIAS status on local progression-free (LPF), regional failure-free (RFF), distant failure-free (DFF), progression-free survival (PFS), and overall survival (OS) rates was assessed using univariate and multivariate analyses.</p></div><div><h3>Results</h3><p>Overall, 68 patients were included. The median follow-up time was 24.3 months. For patients positive/negative for TCIAS, the 2-year LPF, RFF, DFF, PFS, and OS rates were 81.4 %/91.1 %, 73.7 %/96.2 %, 55.9 %/75.3 %, 55.0 %/84.6 %, and 67.8 %/92.2 %, respectively. In the multivariate analysis, TCIAS-positive was a significant unfavorable factor for RFF (hazard ratio [HR]: 4.10; 95 % confidence interval [CI]: 1.04–16.16, p = 0.04), DFF (HR: 2.61, 95 % CI: 1.03–6.57, p = 0.04), and PFS (HR: 2.36; 95 % CI: 1.05–5.30, p = 0.04). By contrast, TCIAS-positive was not a significant risk factor for LPF and OS.</p></div><div><h3>Conclusion</h3><p>TCIAS-positive is an unfavorable factor for regional and distant failure after SBRT. TCIAS status may be useful in predicting the treatment outcome of SBRT for early-stage lung cancer.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100795"},"PeriodicalIF":3.1,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000727/pdfft?md5=be5c84f6e3d515c7888c4ec802ff4014&pid=1-s2.0-S2405630824000727-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141043008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exclusion of non-Involved uterus from the target volume (EXIT-trial): An individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques followed by completion surgery","authors":"Axel Van Damme ,&nbsp;Philippe Tummers ,&nbsp;Pieter De Visschere ,&nbsp;Jo Van Dorpe ,&nbsp;Koen Van de Vijver ,&nbsp;Tom Vercauteren ,&nbsp;Werner De Gersem ,&nbsp;Hannelore Denys ,&nbsp;Eline Naert ,&nbsp;Amin Makar ,&nbsp;Wilfried De Neve ,&nbsp;Katrien Vandecasteele","doi":"10.1016/j.ctro.2024.100793","DOIUrl":"https://doi.org/10.1016/j.ctro.2024.100793","url":null,"abstract":"<div><h3>Background and purpose</h3><p>Chemoradiotherapy followed by brachytherapy is the standard of care for locally advanced cervical cancer (LACC). In this study, we postulate that omitting an iconographical unaffected uterus (+12 mm distance from the tumour) from the treatment volume is safe and that no tumour will be found in the non-targeted uterus (NTU) leading to reduction of high-dose volumes of surrounding organs at risk (OARs)</p></div><div><h3>Material and Methods</h3><p>In this single-arm phase 2 study, two sets of target volumes were delineated: one standard-volume (whole uterus) and an EXIT-volume (exclusion of non-tumour-bearing parts of the uterus with a minimum 12 mm margin from the tumour). All patients underwent chemoradiotherapy targeting the EXIT-volume, followed by completion hysterectomy. In 15 patients, a plan comparison between two treatment plans (PTV vs PTV_EXIT) was performed. The primary endpoint was the pathological absence of tumour involvement in the non-targeted uterus (NTU). Secondary endpoints included dosimetric impact of target volume reduction on OARs, acute and chronic toxicity, overall survival (OS), locoregional recurrence-free survival (LRFS), and progression-free survival (PFS).</p></div><div><h3>Results</h3><p>In all 21 (FIGO stage I: 2; II: 14;III: 3; IV: 2) patients the NTU was pathologically negative. Ssignificant reductions in Dmean in bladder, sigmoid and rectum; V15Gy in sigmoid and rectum, V30Gy in bladder, sigmoid and rectum; V40Gy and V45Gy in bladder, bowel bag, sigmoid and rectum; V50Gy in rectum were achieved. Median follow-up was 54 months (range 7–79 months). Acute toxicity was mainly grade 2 and 5 % grade 3 urinary. The 3y- OS, PFS and LRFS were respectively 76,2%, 64,9% and 81 %.</p></div><div><h3>Conclusion</h3><p>MRI-based exclusion of the non-tumour-bearing parts of the uterus at a minimum distance of 12 mm from the tumour out of the target volume in LACC can be done without risk of residual disease in the NTU, leading to a significant reduction of the volume of surrounding OARS treated to high doses.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100793"},"PeriodicalIF":3.1,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000703/pdfft?md5=99d4b5c5d36719540a84ad89628260a4&pid=1-s2.0-S2405630824000703-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic lymph node motion during cone-beam computed tomography guided stereotactic radiotherapy","authors":"J. Janssen,&nbsp;F.H.E. Staal,&nbsp;J.A. Langendijk,&nbsp;S. Both,&nbsp;C.L. Brouwer,&nbsp;S. Aluwini","doi":"10.1016/j.ctro.2024.100794","DOIUrl":"https://doi.org/10.1016/j.ctro.2024.100794","url":null,"abstract":"<div><h3>Background and purpose</h3><p>Stereotactic body radiotherapy (SBRT) is increasingly applied for pelvic lymph node recurrence. Thus far, knowledge on pelvic lymph node motion during CBCT-guided SBRT is lacking and the applied margins vary between institutions. This study evaluated pelvic lymph node motion during CBCT-guided SBRT and assessed the currently applied PTV margins of 3 and 5 mm.</p></div><div><h3>Material and methods</h3><p>In total, 45 pelvic lymph node metastases were included. One observer delineated 45 GTVs on planning CT, 224 GTVs on pre-fraction and 216 on post-fraction CBCT. The GTV centroid coordinates were derived from all images for inter- and intrafraction motion analysis. Additionally, we assessed the influence of treatment time and lesion location on lesion motion. The expected coverage of a 3-mm and 5-mm PTV margin was assessed using the inclusiveness index for GTVs on pre- and post-fraction CBCT.</p></div><div><h3>Results</h3><p>Lymph node interfraction motion was limited to 5 mm in 96–97 % of fractions for all translational directions and intrafraction lesion motion was limited to 3 mm in 97–100 % of fractions. Para-rectal lesions (11 %) were associated with significantly larger inter- and intrafraction motion compared to other pelvic locations and treatment duration showed no correlation with lesion motion. The mean (sd) lesion inclusiveness index was 99 % (5 %) for the 5-mm PTV margin and 96 % (9 %) for the 3-mm margin.</p></div><div><h3>Conclusion</h3><p>Pelvic lymph node motion during CBCT-guided stereotactic radiotherapy was within the widely applied PTV margin of 5 mm, providing an opportunity to reduce this margin for pelvic lymph node SBRT.</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100794"},"PeriodicalIF":3.1,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000715/pdfft?md5=3ff21fd688f99e0e3a07f4080100e7fb&pid=1-s2.0-S2405630824000715-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140950899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application and progress of artificial intelligence in radiation therapy dose prediction","authors":"Chen Jiang,&nbsp;Tianlong Ji,&nbsp;Qiao Qiao","doi":"10.1016/j.ctro.2024.100792","DOIUrl":"https://doi.org/10.1016/j.ctro.2024.100792","url":null,"abstract":"<div><p>Radiation therapy (RT) nowadays is a main treatment modality of cancer. To ensure the therapeutic efficacy of patients, accurate dose distribution is often required, which is a time-consuming and labor-intensive process. In addition, due to the differences in knowledge and experience among participants and diverse institutions, the predicted dose are often inconsistent. In last several decades, artificial intelligence (AI) has been applied in various aspects of RT, several products have been implemented in clinical practice and confirmed superiority. In this paper, we will review the research of AI in dose prediction, focusing on the progress in deep learning (DL).</p></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"47 ","pages":"Article 100792"},"PeriodicalIF":3.1,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405630824000697/pdfft?md5=19485973fd871948e35b3d07858d4375&pid=1-s2.0-S2405630824000697-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140918080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}